Atlas Trials

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

Clinical trial NCT01657591 · COMPLETED

Trial details

NCT number
NCT01657591
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Melanoma
Start date
2012-07-27
Primary completion
2016-09-20
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.